Gyre Therapeutics President Executes Stock Sales Amid Market Volatility Ma Songjiang, President of Gyre Therapeutics, recently sold 4,000 shares of the company’s stock, totaling $45,480. Transactions were conducted under a pre-arranged Rule 10b5-1 trading plan. Despite a recent 10% stock gain, analysts suggest the shares are overvalued. The company continues advancing its pipeline, including clinical trials for liver fibrosis treatments.12